| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
NIBR3049 primarily targets JAK3 (Janus kinase 3), a member of the JAK family of tyrosine kinases involved in cytokine signaling. JAK3 is predominantly expressed in hematopoietic cells and plays a critical role in immune cell development and function. By inhibiting JAK3, NIBR3049 blocks signaling through common γ-chain cytokines (e.g., IL-2, IL-4, IL-7, IL-9, IL-15, IL-21). The compound also inhibits PKCα, PKCθ, and GSK3β, indicating additional kinase targets.
|
|---|---|
| ln Vitro |
TCS 21311 (NIBR3049) had IC50 values in the enzymatic Jak assay of 1.017, 2.550, and 8.055 μM for JAK1, JAK2, and TYK2, respectively [1]. According to its enzymatic Pkc activity [1], TCS 21311 (NIBR3049) exhibits moderate activity in this cell experiment (IC50=689 nM, Jurkat cells).
In vitro, NIBR3049 potently inhibits JAK3 with an IC₅₀ of 8 nM. It shows >100-fold selectivity over JAK1, JAK2, and TYK2. The compound also inhibits PKCα (IC₅₀ = 13 nM), PKCθ (IC₅₀ = 68 nM), and GSK3β (IC₅₀ = 3 nM). In cellular assays, NIBR3049 inhibits JAK3-mediated STAT5 phosphorylation and downstream gene expression. The compound is used as a tool for studying JAK3 signaling and immune function. |
| ln Vivo |
In vivo data for NIBR3049 are limited in publicly available sources. Based on its potency and selectivity for JAK3, the compound is expected to be useful for in vivo studies of JAK3 function in immune regulation. Its oral bioavailability and solubility (50 mg/mL in DMSO) suggest potential for in vivo administration. Further studies are needed to fully characterize its in vivo efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
In vitro kinase assays for NIBR3049 typically use recombinant JAK3 enzyme and a peptide substrate. The compound is dissolved in DMSO and diluted in assay buffer (50 mM HEPES, pH 7.5, 10 mM MgCl₂, 1 mM EGTA, 0.01% Brij-35, 2 mM DTT). Reactions are initiated by adding ATP (at Km concentration) and incubated at 30°C for 30-60 minutes. Phosphorylated substrate is detected by fluorescence polarization, AlphaScreen, or radiometric methods. IC₅₀ values are calculated from dose-response curves. Selectivity profiling is performed against a panel of kinases including JAK1, JAK2, TYK2, PKCα, PKCθ, and GSK3β.
|
| Cell Assay |
For cell-based assays, immune cell lines (e.g., NK-92, Jurkat, or primary lymphocytes) are cultured in RPMI-1640 with 10% FBS. Cells are seeded in 96-well plates and treated with NIBR3049 at various concentrations (0.001-10 μM) for 1-4 hours. Cells are stimulated with cytokines (e.g., IL-2, IL-15) for 15-30 minutes. STAT5 phosphorylation is measured by phospho-flow cytometry or Western blotting. Cell viability is assessed by MTT or CellTiter-Glo. Proliferation assays may be performed using [³H]-thymidine incorporation. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NIBR3049 may be administered to rodents via IP or oral routes. Dosing regimens and concentrations would be determined based on pharmacokinetic studies. The compound is soluble in DMSO (50 mg/mL) for formulation preparation. Pharmacodynamic studies assess JAK3 inhibition by measuring STAT5 phosphorylation in blood or tissue samples. Efficacy studies may be conducted in autoimmune or inflammatory disease models. Plasma and tissue concentrations are measured by LC-MS/MS. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
NIBR3049 (TCS 21311, MW 526.51, C₂₇H₂₅F₃N₄O₄) is soluble in DMSO (50 mg/mL). The compound shows high potency against JAK3 (IC₅₀ = 8 nM) with >100-fold selectivity over other JAK family members. It also inhibits PKCα, PKCθ, and GSK3β. Detailed pharmacokinetic parameters are available from preclinical studies. The compound is designed for research applications in immunology.
|
| Toxicity/Toxicokinetics |
Toxicology data for NIBR3049 are limited in publicly available sources. As a kinase inhibitor, potential off-target effects should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
NIBR3049 (TCS 21311) is a research-grade JAK3 inhibitor for studying immune signaling and autoimmune diseases. Its primary applications include immunology and inflammation research. The compound is not approved for clinical use and has not entered clinical trials. It is a valuable tool for elucidating the role of JAK3 in cytokine signaling. The compound is commercially available from various chemical suppliers for research purposes only.
|
| Molecular Formula |
C27H25F3N4O4
|
|---|---|
| Molecular Weight |
526.5162
|
| Exact Mass |
526.183
|
| CAS # |
1260181-14-3
|
| PubChem CID |
50925411
|
| Appearance |
White to yellow solid powder
|
| LogP |
3.452
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
38
|
| Complexity |
1000
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CLGRAWDGLMENOD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H25F3N4O4/c1-26(2,38)25(37)34-11-9-33(10-12-34)15-7-8-19(27(28,29)30)17(13-15)21-22(24(36)32-23(21)35)18-14-31-20-6-4-3-5-16(18)20/h3-8,13-14,31,38H,9-12H2,1-2H3,(H,32,35,36)
|
| Chemical Name |
3-[5-[4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
|
| Synonyms |
NIBR 3049 NIBR-3049 NIBR3049
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~189.93 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8993 mL | 9.4963 mL | 18.9926 mL | |
| 5 mM | 0.3799 mL | 1.8993 mL | 3.7985 mL | |
| 10 mM | 0.1899 mL | 0.9496 mL | 1.8993 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
